ONCR | Oncorus, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1205 - 0.1205
52 Week Range	0.1205 - 0.1205
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	26,094,800
Market Cap	3,144,423
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-10-02

Valuation
Profitability
Growth
Health
P/E Ratio	-0.03
Forward P/E Ratio	N/A
EPS	-3.48
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	64
Country	USA
Website	ONCR

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ONCR's peers: AKTX, BNTC, CMMB, EVGN, GTBP, LEXX, RNAZ, TFFP, XBIO

*Chart delayed

Analyzing fundamentals for ONCR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ONCR Fundamentals page.

Watching at ONCR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on ONCR Technicals page.